At Editas, recently-appointed CEO designate Gilmore O’Neill faces several challenges—although he prefers to call them opportunities. The first is shepherding the company’s lead candidate—EDIT-101 for Leber congenital amaurosis-10 (LCA10)—through the rest of its clinical trials towards regulatory approval. Editas’ second challenge is expanding its pipeline by successfully developing other gene editing therapies . . .
The post Current and Future CEOs See Opportunities in Editas’ Challenges appeared first on GEN – Genetic Engineering and Biotechnology News.